BioSpace News Archive

Amprion is pleased to announce its attendance at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in Gothenburg, Sweden on March 28-April 1.

Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving nearly 38 million members nationally, has appointed Mostafa Kamal as president of the organization.

BioSig Technologies, Inc. today announced the appointment of new Advisory Board member Edwin Wang.

Anika Therapeutics, Inc. announced that it has filed its preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming 2023 Annual Meeting of Stockholders.

Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will present and participate in a panel discussion at Jefferies Inaugural Radiopharma Innovation Summit in New York City on Monday, April 3, 2023.

Oncternal Therapeutics, Inc. today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal as Head of IT.

Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced today the appointment of Thomas Ichim, Ph.D., as President, and Chief Executive Officer of Campbell Neurosciences.

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the maytansinoid-based drug delivery systems.

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) data.

NeuroSense Therapeutics Ltd. today announced it has signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital’s NeuroEpigenetics Lab to explore the neurotherapeutic effects of its lead combination drug, PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue (synaptoneurosomes (SNs) system).